European Commission Approves Revolution Medicines’ RASONQUE® (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
The European Commission has approved RASONQUE (daraxonrasib) by Revolution Medicines for treating adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy. The approval, based on positive Phase 3 RASolute 302 trial results, represents a significant advancement for pancreatic cancer treatment in the EU, with the company working to enable patient access through national pricing and reimbursement processes.